CD274 and neoplasm: This method is based on the premise that transcriptome signatures, among various factors (such as PD-L1 expression level9, neoantigen load10, immune infiltration level10, and tumor aneuploidy11) can serve as biomarkers that affect the effectiveness of ICB.